Pharmaceutical companies by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Takeda Pharmaceutical leads the 33 pharmaceutical companies ranked by P/E ratio, at 305, ahead of Merck & Co (139) and Ligand Pharmaceuticals (121). Figures as of 18 Nov 2026, 19:11 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 33
- First
- Takeda Pharmaceutical305
- Median
- 40.1
- Combined market value
- PLN 20.4T
- Countries
- 10
- Not ranked
- 28no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/E ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Takeda PharmaceuticalTAK · Health Care | 305 | PLN 274.2B | PLN 85.83 | 1.39% down | 54% up | ||
| 2 | Merck & CoMRK · Health Care | 139 | PLN 1.37T | PLN 554.21 | 3.89% down | 51% up | ||
| 3 | Ligand PharmaceuticalsLGND · Health Care | 121 | PLN 24.2B | PLN 1,209.58 | 2.36% up | 43% up | ||
| 4 | TG TherapeuticsTGTX · Health Care | 98.3 | PLN 40B | PLN 264.84 | 5.01% up | 107% up | ||
| 5 | Teva Pharmaceutical IndustriesTEVA · Health Care | 97.8 | PLN 197.4B | PLN 169.18 | 1.30% down | 74% up | ||
| 6 | Jazz PharmaceuticalsJAZZ · Health Care | 72.8 | PLN 63.6B | PLN 990.21 | 2.28% up | 37% up | ||
| 7 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 72.0 | PLN 30B | PLN 382.44 | 0.02% down | 126% up | ||
| 8 | Amneal PharmaceuticalsAMRX · Health Care | 54.9 | PLN 30.8B | PLN 88.38 | 4.05% up | 83% up | ||
| 9 | BeOne MedicinesONC · Health Care | 51.8 | PLN 185.7B | PLN 1,625.37 | 2.21% down | 17% up | ||
| 10 | Corcept TherapeuticsCORT · Health Care | 51.0 | PLN 29.8B | PLN 272.64 | 3.25% down | 8% down | ||
| 11 | AbbVieABBV · Health Care | 49.3 | PLN 2.04T | PLN 1,153.77 | 2.03% down | 26% up | ||
| 12 | Royalty PharmaRPRX · Health Care | 45.3 | PLN 160.3B | PLN 278.77 | 0.92% up | 78% up | ||
| 13 | Eli LillyLLY · Health Care | 45.1 | PLN 4.98T | PLN 5,586.09 | 1.88% down | 35% up | ||
| 14 | GenmabGMAB · Health Care | 43.9 | PLN 127.2B | PLN 206.36 | 1.25% down | 70% up | ||
| 15 | Dr. Reddy's LaboratoriesRDY · Health Care | 41.8 | PLN 50.4B | PLN 60.47 | 1.66% up | 5% up | ||
| 16 | Johnson & JohnsonJNJ · Health Care | 41.6 | PLN 2.66T | PLN 1,103.08 | 1.59% down | 38% up | ||
| 17 | PfizerPFE · Health Care | 40.1 | PLN 643.8B | PLN 112.95 | 1.35% down | 14% up | ||
| 18 | Abbott LaboratoriesABT · Health Care | 39.0 | PLN 727.8B | PLN 420.24 | 0.21% down | 17% down | ||
| 19 | Vertex PharmaceuticalsVRTX · Health Care | 34.6 | PLN 548.6B | PLN 2,163.93 | 0.72% up | 27% up | ||
| 20 | NovartisNVS · Health Care | 29.7 | PLN 1.18T | PLN 625.69 | 2.23% down | 25% up | ||
| 21 | Protagonist TherapeuticsPTGX · Health Care | 26.5 | PLN 32.9B | PLN 504.78 | 0.67% up | 46% up | ||
| 22 | AstraZenecaAZN · Health Care | 25.3 | PLN 1.12T | PLN 719.72 | 1.82% down | 2% up | ||
| 23 | SanofiSNY · Health Care | 23.5 | PLN 456.4B | PLN 190.07 | 0.57% down | 4% down | ||
| 24 | United TherapeuticsUTHR · Health Care | 21.9 | PLN 99.6B | PLN 2,337.52 | 0.49% down | 23% up | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 20.9 | PLN 393.3B | PLN 3,801.46 | 1.31% down | 36% up | ||
| 26 | Ascendis PharmaASND · Health Care | 17.8 | PLN 71.4B | PLN 1,089.01 | 0.15% down | 28% up | ||
| 27 | GSKGSK · Health Care | 17.0 | PLN 392.3B | PLN 195.70 | 1.18% down | 6% up | ||
| 28 | ZoetisZTS · Health Care | 14.5 | PLN 139.7B | PLN 343.86 | 2.42% up | 29% down | ||
| 29 | Bristol-Myers SquibbBMY · Health Care | 13.3 | PLN 492.6B | PLN 240.99 | 2.33% down | 34% up | ||
| 30 | GrifolsGRFS · Health Care | 10.2 | PLN 23.1B | PLN 33.88 | 2.38% down | 1% up | ||
| 31 | Novo NordiskNVO · Health Care | 10.0 | PLN 700.6B | PLN 158.96 | 2.89% down | 17% down | ||
| 32 | Alnylam PharmaceuticalsALNY · Health Care | 7.5 | PLN 80.4B | PLN 600.05 | 4.66% down | 66% down | ||
| 33 | Edgewise TherapeuticsEWTX · Health Care | 5.0 | PLN 18.3B | PLN 167.15 | 1.14% down | 88% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 4.0218 PLN). 28 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/E ratio?
Takeda Pharmaceutical (305), Merck & Co (139) and Ligand Pharmaceuticals (121) are the top three of the 33 pharmaceutical companies ranked by P/E ratio as of 18 Nov 2026, 19:11 UTC.
How many pharmaceutical companies are in this ranking?
33 are ranked by P/E ratio. 28 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 33 pharmaceutical companies ranked by P/E ratio have a combined market value of PLN 20.4T as of 18 Nov 2026, 19:11 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.